Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

M. Javle, R. K. Kelley, S. Roychowdhury, K. H. Weiss, G. K. Abou-Alfa, T. Macarulla, S. Sadeghi, D. Waldschmidt, A. X. Zhu, L. Goyal, M. Borad, W. P. Yong, I. Borbath, A. El-Khoueiry, P. Philip, S. Moran, Y. Ye, M. Ising, N. Lewis, T. Bekaii-Saab

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii720
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this